CAR-T therapies are personalized treatments made from patients’ own immune cells. Their production is precisely choreographed, as frozen cells are brought to manufacturing hubs where they are engineered and expanded into a cancer-seeking drug product. It’s laborious, time-consuming and costly.
Currently, CAR-T manufacturers need somewhere between two to three weeks to turn around a therapy for use in treating a patient. Companies like Cellares aim to improve on that standard through a variety of methods, among them automating production and moving manufacturing closer to treatment sites.
